Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
Key Highlights
- ➤Ultrasome™ study found 28 of 30 patients met response criteria after six months
- ➤Average pain scores declined approximately 65% from baseline after six months
- ➤Average WOMAC scores declined 52%, while knee-related quality of life rose approximately 35 points
- ➤No serious adverse events were reported during six months of follow-up
- ➤Ultrasome™ remains investigational and the pilot lacked a randomized or sham-controlled comparator
Expert Statements
Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings
“These findings represent an encouraging milestone for Ultrasome. With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group’s average pain score, we believe the results strengthen the rationale for further development. The additional potency findings reinforce our focus on a scalable, biologically active regenerative medicine platform with significant long-term opportunity.”
PHOENIX, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine technologies, today highlighted additional clinical and laboratory findings for Ultrasome™, its investigational cell-free regenerative medicine platform, following a presentation at the Annual Meeting of Experts in Cell and Gene Therapy held October 10, 2026, in Lima, Peru.
The study evaluated 30 patients with bilateral knee osteoarthritis over six months and found that 28 of 30 participants (93%) met study-defined response criteria. Importantly, the group’s average reported pain score declined by approximately 65% from baseline to six months. The 65% figure refers to the reduction in the group-average pain score - not the percentage of patients reporting improvement.
Get started
Create a free account to read the full story.